Effects of long chain ω-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients

G. Derosa, P. Maffioli, A. D'Angelo, S. A T Salvadeo, I. Ferrari, E. Fogari, A. Gravina, R. Mereu, S. Randazzo, A. F G Cicero

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

We evaluate the effect of a standardized dietary supplementation with ω-3 polyunsaturated fatty acids (n-3 PUFAs) on the level of some markers of vascular remodeling in patients with combined dyslipidemia. Three hundred and thirty-three patients received placebo or n-3 PUFAs for 6 months. We evaluated body mass index, glycemic profile, blood pressure, lipid profile, lipoprotein(a), plasminogen activator inhibitor-1, homocysteine, fibrinogen, high-sensitivity C reactive protein, ADP, MMP-2 and MMP-9, and tissue inhibitors of metalloproteinase-1 and -2. A significant increase of high-density lipoprotein-cholesterol, and a significant decrease of triglycerides were present after 3 and 6 months with n-3 PUFAs intake. A significant plasminogen activator inhibitor-1, fibrinogen and high-sensitivity C reactive protein decrease was obtained after 3 and 6 months and a significant ADP increase was observed after 3 and 6 months of n-3 PUFAs. A significant MMP-2, MMP-9, tissue inhibitors of metalloproteinase-1 and tissue inhibitors of metalloproteinase-2 decrease was obtained after 6 months compared to the baseline value with n-3 PUFAs intake. n-3 PUFAs give a better lipid profile and a better improvement of coagulation, fibrinolytic and inflammatory parameters than placebo. Furthermore, lowers levels of MMP-2, MMP-9 and their tissue inhibitors are obtained with n-3 PUFAs compared to placebo.

Original languageEnglish
Pages (from-to)1239-1247
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume10
Issue number8
DOIs
Publication statusPublished - Jun 2009

Fingerprint

Omega-3 Fatty Acids
Metalloproteases
Dyslipidemias
Matrix Metalloproteinases
Fatty Acids
Tissue Inhibitor of Metalloproteinase-2
Tissue Inhibitor of Metalloproteinase-1
Plasminogen Activator Inhibitor 1
Placebos
C-Reactive Protein
Adenosine Diphosphate
Fibrinogen
Lipids
Lipoprotein(a)
Homocysteine
Dietary Supplements
Unsaturated Fatty Acids
HDL Cholesterol
Triglycerides
Body Mass Index

Keywords

  • ω-3 polyunsaturated fatty acids
  • Combined dyslipidemia
  • Inflammatory parameters
  • Matrix metalloproteinases
  • Tissue inhibitors of metalloproteinases

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Effects of long chain ω-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. / Derosa, G.; Maffioli, P.; D'Angelo, A.; Salvadeo, S. A T; Ferrari, I.; Fogari, E.; Gravina, A.; Mereu, R.; Randazzo, S.; Cicero, A. F G.

In: Expert Opinion on Pharmacotherapy, Vol. 10, No. 8, 06.2009, p. 1239-1247.

Research output: Contribution to journalArticle

@article{ab520e2baed9402dae0ed32335253fa1,
title = "Effects of long chain ω-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients",
abstract = "We evaluate the effect of a standardized dietary supplementation with ω-3 polyunsaturated fatty acids (n-3 PUFAs) on the level of some markers of vascular remodeling in patients with combined dyslipidemia. Three hundred and thirty-three patients received placebo or n-3 PUFAs for 6 months. We evaluated body mass index, glycemic profile, blood pressure, lipid profile, lipoprotein(a), plasminogen activator inhibitor-1, homocysteine, fibrinogen, high-sensitivity C reactive protein, ADP, MMP-2 and MMP-9, and tissue inhibitors of metalloproteinase-1 and -2. A significant increase of high-density lipoprotein-cholesterol, and a significant decrease of triglycerides were present after 3 and 6 months with n-3 PUFAs intake. A significant plasminogen activator inhibitor-1, fibrinogen and high-sensitivity C reactive protein decrease was obtained after 3 and 6 months and a significant ADP increase was observed after 3 and 6 months of n-3 PUFAs. A significant MMP-2, MMP-9, tissue inhibitors of metalloproteinase-1 and tissue inhibitors of metalloproteinase-2 decrease was obtained after 6 months compared to the baseline value with n-3 PUFAs intake. n-3 PUFAs give a better lipid profile and a better improvement of coagulation, fibrinolytic and inflammatory parameters than placebo. Furthermore, lowers levels of MMP-2, MMP-9 and their tissue inhibitors are obtained with n-3 PUFAs compared to placebo.",
keywords = "ω-3 polyunsaturated fatty acids, Combined dyslipidemia, Inflammatory parameters, Matrix metalloproteinases, Tissue inhibitors of metalloproteinases",
author = "G. Derosa and P. Maffioli and A. D'Angelo and Salvadeo, {S. A T} and I. Ferrari and E. Fogari and A. Gravina and R. Mereu and S. Randazzo and Cicero, {A. F G}",
year = "2009",
month = "6",
doi = "10.1517/14656560902865601",
language = "English",
volume = "10",
pages = "1239--1247",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "8",

}

TY - JOUR

T1 - Effects of long chain ω-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients

AU - Derosa, G.

AU - Maffioli, P.

AU - D'Angelo, A.

AU - Salvadeo, S. A T

AU - Ferrari, I.

AU - Fogari, E.

AU - Gravina, A.

AU - Mereu, R.

AU - Randazzo, S.

AU - Cicero, A. F G

PY - 2009/6

Y1 - 2009/6

N2 - We evaluate the effect of a standardized dietary supplementation with ω-3 polyunsaturated fatty acids (n-3 PUFAs) on the level of some markers of vascular remodeling in patients with combined dyslipidemia. Three hundred and thirty-three patients received placebo or n-3 PUFAs for 6 months. We evaluated body mass index, glycemic profile, blood pressure, lipid profile, lipoprotein(a), plasminogen activator inhibitor-1, homocysteine, fibrinogen, high-sensitivity C reactive protein, ADP, MMP-2 and MMP-9, and tissue inhibitors of metalloproteinase-1 and -2. A significant increase of high-density lipoprotein-cholesterol, and a significant decrease of triglycerides were present after 3 and 6 months with n-3 PUFAs intake. A significant plasminogen activator inhibitor-1, fibrinogen and high-sensitivity C reactive protein decrease was obtained after 3 and 6 months and a significant ADP increase was observed after 3 and 6 months of n-3 PUFAs. A significant MMP-2, MMP-9, tissue inhibitors of metalloproteinase-1 and tissue inhibitors of metalloproteinase-2 decrease was obtained after 6 months compared to the baseline value with n-3 PUFAs intake. n-3 PUFAs give a better lipid profile and a better improvement of coagulation, fibrinolytic and inflammatory parameters than placebo. Furthermore, lowers levels of MMP-2, MMP-9 and their tissue inhibitors are obtained with n-3 PUFAs compared to placebo.

AB - We evaluate the effect of a standardized dietary supplementation with ω-3 polyunsaturated fatty acids (n-3 PUFAs) on the level of some markers of vascular remodeling in patients with combined dyslipidemia. Three hundred and thirty-three patients received placebo or n-3 PUFAs for 6 months. We evaluated body mass index, glycemic profile, blood pressure, lipid profile, lipoprotein(a), plasminogen activator inhibitor-1, homocysteine, fibrinogen, high-sensitivity C reactive protein, ADP, MMP-2 and MMP-9, and tissue inhibitors of metalloproteinase-1 and -2. A significant increase of high-density lipoprotein-cholesterol, and a significant decrease of triglycerides were present after 3 and 6 months with n-3 PUFAs intake. A significant plasminogen activator inhibitor-1, fibrinogen and high-sensitivity C reactive protein decrease was obtained after 3 and 6 months and a significant ADP increase was observed after 3 and 6 months of n-3 PUFAs. A significant MMP-2, MMP-9, tissue inhibitors of metalloproteinase-1 and tissue inhibitors of metalloproteinase-2 decrease was obtained after 6 months compared to the baseline value with n-3 PUFAs intake. n-3 PUFAs give a better lipid profile and a better improvement of coagulation, fibrinolytic and inflammatory parameters than placebo. Furthermore, lowers levels of MMP-2, MMP-9 and their tissue inhibitors are obtained with n-3 PUFAs compared to placebo.

KW - ω-3 polyunsaturated fatty acids

KW - Combined dyslipidemia

KW - Inflammatory parameters

KW - Matrix metalloproteinases

KW - Tissue inhibitors of metalloproteinases

UR - http://www.scopus.com/inward/record.url?scp=67649675091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649675091&partnerID=8YFLogxK

U2 - 10.1517/14656560902865601

DO - 10.1517/14656560902865601

M3 - Article

C2 - 19397392

AN - SCOPUS:67649675091

VL - 10

SP - 1239

EP - 1247

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 8

ER -